Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.76 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959593 | 1.00 | CHRNB2 (0.76) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL30241910 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL30241909 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL1462348 | 0.98 | CHRNB2 (0.73) | CHRNB2CHRNA4CHKACHRNA7CHRNA1 | |
| SCHEMBL11544331 | 0.96 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL6352765 | 0.88 | CHRNB2 (0.61) | CHRNB2CHRNA4 | |
| SCHEMBL5655866 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL6350076 | 0.86 | CHRNB2 (0.91) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG | |
| SCHEMBL5655570 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4CHKA | |
| SCHEMBL3061045 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119657051-A | Temperature control method and reaction device of thermotropic liquid crystal polyester synthesis reaction kettle | 浙江聚领新材料有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-115074789-B | Circuit board blind hole rapid filling electrolytic copper plating solution and rapid filling method | 深圳市板明科技股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115074789-A | Circuit board blind hole rapid filling electrolytic copper plating solution and rapid filling method | 深圳市板明科技股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | claimed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | claimed |
| EP-0421762-A1 | Novel nicotine analogs and method | Philip Morris Products Inc. (US) | 1991-04-10 | — | — | EP | claimed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| US-4915868-A | Display element | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2154/4885CHRNA4 1666/4885CHKA 2754/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | CHRNB2 69/4885CHRNA4 178/4885CHKA 206/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2154/4885CHRNA4 1666/4885CHKA 2754/4885 |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NAPRT | CHRNB2 2269/4885CHRNA4 1734/4885CHKA 2529/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2154/4885CHRNA4 1666/4885CHKA 2754/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2937/4885CHRNA4 2264/4885CHKA 2831/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2937/4885CHRNA4 2264/4885CHKA 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.